Zhaoke Ophthalmology’s Partner Vyluma Announces Positive Results from Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children

Zhaoke Ophthalmology Named as a “China Top 30 Innovative Small Molecule Drug Developer” on the “2021 China Top 100 Innovative Biotech Companies List”

Zhaoke Ophthalmology Announces 2022 Interim Results

First Patient Enrolled in Phase II Clinical Trial of Zhaoke Ophthalmology’s ZKY001 For Transepithelial Photorefractive Keratectomy (TPRK)

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002